From the CMS doc “Medicare Drug Value Negotiation Program: Chosen Medicine for Preliminary Value
Applicability 12 months 2027“:
On January 17, 2025, CMS introduced the choice of the beneath checklist of 15 medication coated beneath Medicare Half D for the second cycle of negotiations (preliminary value applicability 12 months 2027), primarily based on whole gross coated prescription drug prices beneath Medicare Half D and different standards as required by the regulation.
With the Trump inauguration to happen on Monday, will the Medicare Drug Value Negotiation course of change with the brand new administration? Anna Kaltenboeck notes in EndPoints Information:
…the following administration is not going to have “blanket authority to alter the core components of the regulation,” sure elements of the method might be modified with out legislative motion.
For instance, CMS may alter its steerage or the way it interprets components of the regulation, resembling what number of occasions it meets with drugmakers, or what number of listening classes it holds. “The diploma to which they play hardball with producers within the course of may change,” she mentioned.
